We are live on ! Find out more
JUNO

Juno Therapeutics, Inc.
JUNO

Delisted

JUNO was delisted on the 5th of March, 2018.

Back to rankings

132 hedge funds and large institutions have $2.17B invested in Juno Therapeutics, Inc. in 2015 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 54 increasing their positions, 28 reducing their positions, and 56 closing their positions.

New
Increased
Maintained
Reduced
Closed

93% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 28

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

14% less funds holding

Funds holding: 154 → 132 (-22)

14% less capital invested

Capital invested by funds: $2.54B → $2.17B (-$365M)

34% less call options, than puts

Call options by funds: $29.5M | Put options by funds: $44.9M

38% less first-time investments, than exits

New positions opened: 35 | Existing positions closed: 56

Holders
132
Holders Change
-22
Holders Change %
-14.29%
% of All Funds
3.68%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
35
Increased
54
Reduced
28
Closed
56
Calls
$29.5M
Puts
$44.9M
Net Calls
-$15.4M
Net Calls Change
+$15.4M

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$131M
2
BB
BB Biotech
Switzerland
+$37.5M
3
BIT
BlackRock Institutional Trust
California
+$29M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$23.7M
5
State Street
State Street
Massachusetts
+$14.3M

Top Sellers

Rank Fund Capital Flow
1
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$16.3M
2
Citadel Advisors
Citadel Advisors
Florida
-$15.6M
3
RCM
RA Capital Management
Massachusetts
-$14.9M
4
JP Morgan Chase
JP Morgan Chase
New York
-$13.2M
5
DM
Deerfield Management
New York
-$9.77M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fifth Third Bancorp
126
Fifth Third Bancorp
Ohio
$8K +$8.11K +185 New
SFPIA
127
Stevens First Principles Investment Advisors
California
$8K +$8.77K +200 New
QCG
128
Quadrant Capital Group
Ohio
$7K +$8.11K +185 New
FFC
129
First Financial Corp
Indiana
$6K +$6.58K +150 New
MS
130
Marshall & Sullivan
Washington
$4K +$5.48K +125 New
PAI
131
Pittenger & Anderson Inc
Nebraska
$3K +$3.29K +75 New
RCM
132
RA Capital Management
Massachusetts
– -$14.9M -280,000 Closed
DM
133
Deerfield Management
New York
– -$9.77M -183,149 Closed
PP
134
PDT Partners
New York
– -$5.47M -102,658 Closed
FCMI
135
Foresite Capital Management II
California
– -$4.88M -91,575 Closed
VM
136
VHCP Management
New York
– -$4.81M -90,206 Closed
HCMT
137
Highland Capital Management (Texas)
Texas
– -$4.27M -80,000 Closed
CS
138
Credit Suisse
Switzerland
– -$3M -56,151 Closed
GCP
139
GSA Capital Partners
United Kingdom
– -$2.92M -54,700 Closed
Arrowstreet Capital
140
Arrowstreet Capital
Massachusetts
– -$2.64M -49,500 Closed
Group One Trading
141
Group One Trading
Illinois
– -$2.15M -49,031 Closed
Axa
142
Axa
France
– -$1.72M -32,279 Closed
DP
143
DSAM Partners
United Kingdom
– -$1.48K -27,773 Closed
BL
144
Bolton LP
Connecticut
– -$1.37M -25,700 Closed
CC
145
CQS Cayman
Cayman Islands
– -$1.33M -25,000 Closed
SGH
146
Sivik Global Healthcare
Connecticut
– -$1.07M -20,000 Closed
OTPPB
147
Ontario Teachers' Pension Plan Board
Ontario, Canada
– -$902K -16,914 Closed
CA
148
Commerzbank Aktiengesellschaft
Germany
– -$809K -15,174 Closed
VAM
149
Visium Asset Management
New York
– -$710K -13,304 Closed
HLA
150
Hamilton Lane Advisors
Pennsylvania
– -$669K -12,552 Closed
4 5
6
7 8

JUNO Hedge Fund Activity: Q3 2015 in Review

132 of the 3,583 institutional investors tracked by Wall St. Rank reported a position in Juno Therapeutics, Inc. (JUNO) for Q3 2015, worth a combined $2.17B — down 14% from $2.54B a quarter earlier.

Sellers outnumbered buyers: 56 funds closed out of JUNO and 35 opened new positions — a net loss of 21 holders — while 28 trimmed existing stakes and 54 added.

The largest buyer was Vanguard Group, adding an estimated $131M. The largest seller was Lord, Abbett & Co, cutting an estimated $16.3M.

  • 132 institutional investors held Juno Therapeutics, Inc. (JUNO) as of Q3 2015, down from 154 in Q2 2015.
  • Funds reported $2.17B of Juno Therapeutics, Inc. stock for Q3 2015, down 14% quarter-over-quarter.
  • 35 funds opened new Juno Therapeutics, Inc. positions in Q3 2015 and 56 closed out, a net change of -21 holders.
  • The largest Juno Therapeutics, Inc. buyer in Q3 2015 was Vanguard Group, an estimated $131M added.
  • The largest Juno Therapeutics, Inc. seller in Q3 2015 was Lord, Abbett & Co, an estimated $16.3M sold.

Based on aggregated 13F filings for Q3 2015.